Zota Health Care Limited announced the outcome of its Board Meeting held on February 4, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. In strategic moves, the company approved the acquisition of 100% stake in Curexis Ventures Private Limited for ₹10,00,000. Curexis, incorporated on February 25, 2025, is involved in drug manufacturing, development, marketing, and operates retail pharmacy stores under the brand name “SKIA”. Additionally, Zota Health Care acquired 58,827 equity shares of its Wholly Owned Subsidiary, Davaindia Health Mart Limited, through a rights issue for ₹25,29,56,100. Davaindia Health Mart Limited operates a generic pharmacy chain and had a turnover of ₹109.93 crore in FY 2024-25. The Board also approved the constitution of a Risk Management Committee comprising Mr. Moxesh Ketanbhai Zota (Chairperson), Mr. Himanshu Muktilal Zota (Member), and Mr. Dhaval Chandubhai Patwa (Member). The Board meeting concluded at 6:15 P.M.
